Spero Therapeutics (SPRO)
1.27
-0.11 (7.97%)
Upcoming Events
Latest Headlines
Form 8-K Spero Therapeutics, Inc. For: Jul 08
July 14, 2026 6:30 AM - SEC Filing
Spero Therapeutics shares fall after $105M KKR deal
July 14, 2026 6:21 AM - StreetInsider
Spero Therapeutics secures $105M royalty-backed financing deal
July 14, 2026 6:04 AM - StreetInsider
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
July 14, 2026 6:02 AM - Globe NewsWire
Spero Therapeutics licenses Innovent antibody in deal worth up to $1.1B
July 14, 2026 6:00 AM - StreetInsider
Spero Therapeutics licenses antibody from Innovent in $1.1B deal
July 14, 2026 6:00 AM - StreetInsider
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
July 14, 2026 6:00 AM - PR NewsWire
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
July 14, 2026 6:00 AM - Globe NewsWire
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
July 8, 2026 2:00 AM - StreetInsider
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
June 29, 2026 7:30 AM - Globe NewsWire
Form 4 Spero Therapeutics, Inc. For: Jun 23 Filed by: Deshpande Milind
June 25, 2026 7:27 PM - SEC Filing
Form 4 Spero Therapeutics, Inc. For: Jun 23 Filed by: Tregoning Kathleen
June 25, 2026 7:17 PM - SEC Filing
Form 4 Spero Therapeutics, Inc. For: Jun 23 Filed by: Smith Cynthia
June 25, 2026 7:15 PM - SEC Filing
Form 4 Spero Therapeutics, Inc. For: Jun 23 Filed by: VINK PATRICK V.J.J.
June 25, 2026 7:12 PM - SEC Filing
Form 4 Spero Therapeutics, Inc. For: Jun 23 Filed by: THOMAS FRANK E
June 25, 2026 7:00 PM - SEC Filing
Form 4 Spero Therapeutics, Inc. For: Jun 23 Filed by: Jackson Scott Thomas
June 25, 2026 6:58 PM - SEC Filing
Form 4 Spero Therapeutics, Inc. For: Jun 23 Filed by: Pottage John C Jr
June 25, 2026 6:56 PM - SEC Filing
Form 8-K Spero Therapeutics, Inc. For: Jun 23
June 25, 2026 5:09 PM - SEC Filing
Form S-8 Spero Therapeutics, Inc.
June 23, 2026 4:06 PM - SEC Filing
Form 8-K Spero Therapeutics, Inc. For: Jun 17
June 22, 2026 4:05 PM - SEC Filing
FDA approves GSK and Spero's oral carbapenem antibiotic Utebzi
June 17, 2026 4:21 PM - StreetInsider
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
June 17, 2026 4:21 PM - BizWire
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
June 17, 2026 12:36 PM - Globe NewsWire
GSK receives FDA approval for oral antibiotic to treat UTIs
June 17, 2026 11:09 AM - StreetInsider
Compass Pathways elects Kathleen Tregoning to board of directors
May 28, 2026 6:30 AM - StreetInsider
Compass Pathways Elects Kathleen Tregoning to Board of Directors
May 28, 2026 6:30 AM - BizWire
SmartPros Ltd. (SPRO) Reports Q1 Loss of $0.13
May 13, 2026 4:09 PM - StreetInsider
Form 10-Q Spero Therapeutics, Inc. For: Mar 31
May 13, 2026 4:06 PM - SEC Filing
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
May 13, 2026 4:05 PM - Globe NewsWire
Form 8-K Spero Therapeutics, Inc. For: May 13
May 13, 2026 4:02 PM - SEC Filing
Form 4 Spero Therapeutics, Inc. For: May 04 Filed by: Rajavelu Esther
May 6, 2026 9:54 PM - SEC Filing
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
May 5, 2026 4:05 PM - Globe NewsWire
Form ARS Spero Therapeutics, Inc. For: Dec 31
April 27, 2026 4:43 PM - SEC Filing
Form DEFA14A Spero Therapeutics, Inc.
April 27, 2026 4:39 PM - SEC Filing
Form DEF 14A Spero Therapeutics, Inc. For: Jun 23
April 27, 2026 4:31 PM - SEC Filing
Full Article List
